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“We won’t swallow it” (Daily
Mirror) and “GM comes a cropper
as Britain says a huge No” (Daily
Express) were typical headlines
greeting the results of the UK’s
public consultation on GM food.
The government-funded “GM
Nation?” survey showed that only
2% of people would eat it. 95%
were worried that growing GM
plants would contaminate non-GM
ones, 93% felt not enough was
known about long-term health
effects and 84% believed GM
technology represented
unacceptable interference with
nature.
Unambiguous data. Yet the
Daily Mail embellished even these
damning statistics with massive
typefaces, graphic pie charts and
a half-page picture of the Grim
Reaper. In self-congratulatory
mood, the newspaper brandished
the findings as the latest chapter
in its long-running “Frankenstein
Food Watch”.
“The saga of New Labor and
GM food stands as a symbol of all
that is rotten about this
administration,” said an
accompanying editorial. “Mr
Blair’s likely reaction will be to
force GM on us against our will.
He is expected to argue that under
European Union legislation, and
world trade rules, he has no
option. This is rubbish.”
But there were some surprising
reactions too. The Financial
Times, for example, might have
been expected to show weary
frustration on behalf of companies
eager to move ahead
commercially with GM foods. It
may reasonably have argued that
the outcome of the exercise was
hardly surprising after years of
hysteria and misinformation.
Instead, the FT offered
“congratulations to the
government for asking people
what they think about GM crops”.
Most people, said an editorial, had
an intelligent understanding of the
issues, rational scepticism about
the benefits and a healthy mistrust
of GM advocates. “Consumers
simply do not want to buy the
produce...And in a small, windy
island, segregation of crops is
very hard, yet cross-pollination
could ruin organic farming.”
Not a word here to tell readers
that we already cultivate, without
any problems whatever, crops
which are capable of cross-
pollination but which would cause
very serious health dangers if this
were to happen. Oilseed rape
destined for the human food
chain, for example, is simply
grown sufficiently far away from
another variety, which contains
the poison erucic acid, so that for
all practical purposes cross-
fertilisation does not occur.
Also unpredictable was an
article by Geoffrey Lean, who has
led The Independent’s vigorous
campaign against GM food for
several years. The outcome of the
survey, he said, “greatly
exaggerates the scale of public
opposition to GM crops and
food.” Lean pointed out, correctly,
that other opinion polls have
revealed only three-to-one
opposition, with huge numbers of
people undecided. Just a few
months ago, MORI reported that
14% of people favored the
technology, while 46% rejected it
and 40% had yet to make up their
minds.
Lean’s motive was, of course, to
mock the government for scoring
an own goal in a futile quest for
even better figures. “They set up
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the public debate, not as a
genuine search for the public
view, but as a way of getting
greater acceptance,” he wrote.
“Now they are hoist with their own
petard. The people who registered
their views were more hostile than
the public at large.”
The figures were drawn from
over 600 public meetings
throughout the country — which,
as The Independent pointed out,
were not designed to achieve a
cross-sample of the population at
large. “Indeed, there is a case for
saying that there is a ‘self-
selecting’ effect at work in such a
consultation exercise, because
those most likely to turn up to
such a meeting might be
expected to be those most
passionately opposed to GM
products.”
The Times insisted that the
results had particular force
because they did not come solely
from meetings packed with
opponents. “The findings were
confirmed by 77 people who were
selected randomly as
representative of the general
public, a grouping named
‘Narrow-But-Deep’. The panel
was less dogmatic in its
opposition to GM but wished the
government to delay a decision
until there were more tests.”
A third surprise was the
response of The Guardian, which
in 1999 highlighted Arpad
Pusztai’s claims about alleged
dangers of GM crops, and whose
editor co-authored the anti-GM
television drama Fields of Gold
last year. Though it carried two
articles on the survey results, The
Guardian devoted as much space
to a piece warning that “public
antipathy toward GM crops is
driving Britain’s leading plant
scientists to seek greener
pastures abroad”.
Prominent among researchers
quoted was Richard Flavell,
formerly of the John Innes Centre
in Norwich and now with Ceres in
California. “The situation is more
disturbing in the UK than
anywhere else in the world,”
Flavell was quoted as saying.
“The untruths, lies and lack of
orchestrated information make it
impossible for the average person
to make an informed decision.” So
“GM Nation?” (who on earth
decided to call it that?) did not
spawn a uniform, hysterical
chorus from the media. True, most
journalists and editors decided to
amplify its negative verdicts. But a
significant minority urged caution.
Of these, The Times struck
arguably the most appropriate
note. Citing both “scaremongering
about health effects” and
“genuine scientific uncertainty
about environmental effects”, it
concluded that the British people
“do not want to close the door,
but have questions that need
answers”.
Bernard Dixon is the European editor
for the American Society of
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If you have billions of dollars to
spend on good causes, the
choices can be hard. Which
diseases can be eradicated, how
many lives can be saved from
misery and untimely death?
Should I address the acute
problems first, or think long-term
and tackle the chronic issues?
Microsoft founder Bill Gates, who
has pledged to return his
immense fortune to society before
he dies, is facing these kinds of
questions now. And it appears
that he has found some sensible
answers.
The Bill and Melinda Gates Foun-
dation (www.gatesfoundation.org)
currently weighs in at 25 billion US
dollars, that is more than twice the
value of the Wellcome Trust, one of
the world’s largest charitable
foundations for the support of
biomedical research in the UK and
elsewhere. The foundation is based
at Seattle and led by Bill Gates’
father, William H. Gates, Sr., and
former Microsoft manager Patty
Stonesifer. Originally, the founda-
tion was focused mainly on educa-
tion, but when Gates discovered
the catastrophic state of world
health from reading the 1993
edition of the World Bank’s World
Development Report, he swiftly
decided to throw his money at the
most urgent problems in this field.
And the most urgent problems
tend to be located in sub-saharan
Africa, where the double
onslaught of AIDS and of the
traditional tropical diseases
including malaria costs many
millions of lives every year. Some
of the first funding initiatives of the
Gates foundation in Africa are
already bearing fruit. One is
addressing the AIDS problem in
Botswana, the other is a major
immunization initiative which has
already delivered vaccines to
millions of children.
Their next target is malaria, and
it is a worthwhile target if ever
there was one. Although attempts
to control malaria have been
made over many decades, and
there are programmes to support
research from many bodies
including the WHO, mortality from
this disease is currently
increasing, as resistance genes
against the common drugs spread
among the populations of the
deadliest malaria parasite,
Plasmodium falciparum, and there
is a shortage of new drugs.
Further contributing factors
include insecticide resistance in
the Anopheles mosquitoes which
carry the parasite, and wars
leading to diseases spreading
among refugee populations. While
Africans who survive into
adulthood tend to have acquired a
certain degree of immunity, the
mortality is highest among young
children and pregnant women. All
this adds up to over one million
deaths per year, and crippling
costs to the African economies.
All recent initiatives have failed to
‘roll back malaria’, as one program
was enthusiastically entitled, or
even dent its progress, mainly
because they were drastically
under-funded.
On their recent visit to
Mozambique, the Gateses
announced a $168 million funding
initiative to tackle malaria. To put
the number into perspective, this
is about the same order of
magnitude as the global annual
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The software billionaire, Bill
Gates, is determined to spend
some of his fortune on good
causes, including research on
malaria. Michael Gross reports.
